Macrolide Antibiotics Market Research Report - Forecast Till 2032

Macrolide Antibiotics Market Research Report Information By Drugs (Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin, and Telithromycin), By Route of Administration (Oral and Parenteral), By Indication (Infection Due to Mycoplasma Pneumoniae, Legionella Sp, or Bordetella Pertussis, Symptomatic Cat-Scratch Disease, Bacillary Angiomatosis, Peliosis Hepatis in Patients with AIDS, Cerebral Toxoplasmosis, Uncomplicated Skin Infections, and Others), By End User (Hospitals, Dermatology Clinics, Pharmaceutical Companies, and Others) and By Re

ID: MRFR/Pharma/2956-HCR | 200 Pages | Author: Kinjoll Dey | March 2024         

Brief TOC

1 Report Prologue

2 Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3 Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4 Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porters five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain

5.3 Investment Feasibility Analysis

5.4 Price Factor Analysis

6. Global Macrolide Antibiotics Market, by Drug

6.1 Introduction

6.2 Azithromycin

6.3 Clarithromycin

6.4 Erythromycin

6.5 Fidaxomicin

6.6 Telithromycin

7. Global Macrolide Antibiotics Market, by Route of Administration

7.1 Introduction

7.2 Infection Due to Mycoplasma Pneumonia, Legionella Sp, or Bordetella pertussis

7.3 Symptomatic Cat-scratch Disease

7.4 Bacillary Angiomatosis

7.5 Peliosis Hepatis in Patients with AIDS

7.6 Cerebral Toxoplasmosis

7.7 Uncomplicated Skin Infections

7.8 Others

7.8.1 Babesiosis

7.8.2 Chlamydia Trachomatis Urethritis and Cervicitis

8. Global Macrolide Antibiotics Market, by End User

8.1 Introduction

8.2 Hospitals

8.3 Dermatology Clinics

8.4 Pharmaceutical Companies

8.5 Others
9. Global Macrolide Antibiotics Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 UK

9.3.1.4 Italy

9.3.1.5 Spain

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Republic of Korea

9.4.5 Australia

9.4.6 Rest of Asia Pacific

9.5 Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of Middle East & Africa

10 Company Landscape

10.1 Introduction

10.2 Market share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

11 Company Profiles

11.1 Merck Sharp & Dohme Corp

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Pfizer Inc.

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Teva Pharmaceutical Industries Ltd.

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Fresenius Kabi USA

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Sandoz International GmbH

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Macrolide Pharmaceuticals

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 Neo Química

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Healthcare Industry

13 Appendix

Macrolide Antibiotics Market Segmentation Tab


Macrolide Antibiotics Drugs Outlook (USD Billion, 2018-2032)




  • Azithromycin




  • Clarithromycin




  • Erythromycin




  • Fidaxomicin




  • Telithromycin




Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)




  • Oral




  • Parenteral




Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)




  • Infection due to mycoplasma pneumonia




  • Legionella sp,or Bordetella pertussis




  • Symptomatic cat-scratch disease




  • Bacillary angiomatosis




  • Peliosis hepatis in patients with AIDS




  • Cebebral taxoplasmosis




  • Uncomplicated skin infection




  • Others




Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)




  • Hospitals




  • Dermatology clinics




  • Pharmaceutical companies




  • Others




Macrolide Antibiotics Regional Outlook (USD Billion, 2018-2032)




  • North America Outlook (USD Billion, 2018-2032)




    • Macrolide Antibiotics by Drugs




      • Azithromycin




      • Clarithromycin




      • Erythromycin




      • Fidaxomicin




      • Telithromycin






    • Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)




      • Oral




      • Parenteral






    • Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)




      • Infection due to mycoplasma pneumonia




      • Legionella sp,or Bordetella pertussis




      • Symptomatic cat-scratch disease




      • Bacillary angiomatosis




      • Peliosis hepatis in patients with AIDS




      • Cebebral taxoplasmosis




      • Uncomplicated skin infection




      • Others






    • Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Dermatology clinics




      • Pharmaceutical companies




      • Others






    • US Outlook (USD Billion, 2018-2032)




    • Macrolide Antibiotics by Drugs




      • Azithromycin




      • Clarithromycin




      • Erythromycin




      • Fidaxomicin




      • Telithromycin






    • Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)




      • Oral




      • Parenteral






    • Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)




      • Infection due to mycoplasma pneumonia




      • Legionella sp,or Bordetella pertussis




      • Symptomatic cat-scratch disease




      • Bacillary angiomatosis




      • Peliosis hepatis in patients with AIDS




      • Cebebral taxoplasmosis




      • Uncomplicated skin infection




      • Others






    • Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Dermatology clinics




      • Pharmaceutical companies




      • Others






    • Canada Outlook (USD Billion, 2018-2032)




    • Macrolide Antibiotics by Drugs




      • Azithromycin




      • Clarithromycin




      • Erythromycin




      • Fidaxomicin




      • Telithromycin






    • Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)




      • Oral




      • Parenteral






    • Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)




      • Infection due to mycoplasma pneumonia




      • Legionella sp,or Bordetella pertussis




      • Symptomatic cat-scratch disease




      • Bacillary angiomatosis




      • Peliosis hepatis in patients with AIDS




      • Cebebral taxoplasmosis




      • Uncomplicated skin infection




      • Others






    • Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Dermatology clinics




      • Pharmaceutical companies




      • Others








  • Europe Outlook (USD Billion, 2018-2032)




    • Macrolide Antibiotics by Drugs




      • Azithromycin




      • Clarithromycin




      • Erythromycin




      • Fidaxomicin




      • Telithromycin






    • Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)




      • Oral




      • Parenteral






    • Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)




      • Infection due to mycoplasma pneumonia




      • Legionella sp,or Bordetella pertussis




      • Symptomatic cat-scratch disease




      • Bacillary angiomatosis




      • Peliosis hepatis in patients with AIDS




      • Cebebral taxoplasmosis




      • Uncomplicated skin infection




      • Others






    • Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Dermatology clinics




      • Pharmaceutical companies




      • Others






    • Germany Outlook (USD Billion, 2018-2032)




    • Macrolide Antibiotics by Drugs




      • Azithromycin




      • Clarithromycin




      • Erythromycin




      • Fidaxomicin




      • Telithromycin






    • Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)




      • Oral




      • Parenteral






    • Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)




      • Infection due to mycoplasma pneumonia




      • Legionella sp,or Bordetella pertussis




      • Symptomatic cat-scratch disease




      • Bacillary angiomatosis




      • Peliosis hepatis in patients with AIDS




      • Cebebral taxoplasmosis




      • Uncomplicated skin infection




      • Others






    • Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Dermatology clinics




      • Pharmaceutical companies




      • Others






    • France Outlook (USD Billion, 2018-2032)




    • Macrolide Antibiotics by Drugs




      • Azithromycin




      • Clarithromycin




      • Erythromycin




      • Fidaxomicin




      • Telithromycin






    • Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)




      • Oral




      • Parenteral






    • Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)




      • Infection due to mycoplasma pneumonia




      • Legionella sp,or Bordetella pertussis




      • Symptomatic cat-scratch disease




      • Bacillary angiomatosis




      • Peliosis hepatis in patients with AIDS




      • Cebebral taxoplasmosis




      • Uncomplicated skin infection




      • Others






    • Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Dermatology clinics




      • Pharmaceutical companies




      • Others






    • UK Outlook (USD Billion, 2018-2032)




    • Macrolide Antibiotics by Drugs




      • Azithromycin




      • Clarithromycin




      • Erythromycin




      • Fidaxomicin




      • Telithromycin






    • Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)




      • Oral




      • Parenteral






    • Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)




      • Infection due to mycoplasma pneumonia




      • Legionella sp,or Bordetella pertussis




      • Symptomatic cat-scratch disease




      • Bacillary angiomatosis




      • Peliosis hepatis in patients with AIDS




      • Cebebral taxoplasmosis




      • Uncomplicated skin infection




      • Others






    • Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Dermatology clinics




      • Pharmaceutical companies




      • Others






    • Italy Outlook (USD Billion, 2018-2032)




    • Macrolide Antibiotics by Drugs




      • Azithromycin




      • Clarithromycin




      • Erythromycin




      • Fidaxomicin




      • Telithromycin






    • Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)




      • Oral




      • Parenteral






    • Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)




      • Infection due to mycoplasma pneumonia




      • Legionella sp,or Bordetella pertussis




      • Symptomatic cat-scratch disease




      • Bacillary angiomatosis




      • Peliosis hepatis in patients with AIDS




      • Cebebral taxoplasmosis




      • Uncomplicated skin infection




      • Others






    • Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Dermatology clinics




      • Pharmaceutical companies




      • Others






    • Spain Outlook (USD Billion, 2018-2032)




    • Macrolide Antibiotics by Drugs




      • Azithromycin




      • Clarithromycin




      • Erythromycin




      • Fidaxomicin




      • Telithromycin






    • Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)




      • Oral




      • Parenteral






    • Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)




      • Infection due to mycoplasma pneumonia




      • Legionella sp,or Bordetella pertussis




      • Symptomatic cat-scratch disease




      • Bacillary angiomatosis




      • Peliosis hepatis in patients with AIDS




      • Cebebral taxoplasmosis




      • Uncomplicated skin infection




      • Others






    • Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Dermatology clinics




      • Pharmaceutical companies




      • Others






    • Rest Of Europe Outlook (USD Billion, 2018-2032)




    • Macrolide Antibiotics by Drugs




      • Azithromycin




      • Clarithromycin




      • Erythromycin




      • Fidaxomicin




      • Telithromycin






    • Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)




      • Oral




      • Parenteral






    • Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)




      • Infection due to mycoplasma pneumonia




      • Legionella sp,or Bordetella pertussis




      • Symptomatic cat-scratch disease




      • Bacillary angiomatosis




      • Peliosis hepatis in patients with AIDS




      • Cebebral taxoplasmosis




      • Uncomplicated skin infection




      • Others






    • Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Dermatology clinics




      • Pharmaceutical companies




      • Others








  • Asia-Pacific Outlook (USD Billion, 2018-2032)




    • Macrolide Antibiotics by Drugs




      • Azithromycin




      • Clarithromycin




      • Erythromycin




      • Fidaxomicin




      • Telithromycin






    • Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)




      • Oral




      • Parenteral






    • Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)




      • Infection due to mycoplasma pneumonia




      • Legionella sp,or Bordetella pertussis




      • Symptomatic cat-scratch disease




      • Bacillary angiomatosis




      • Peliosis hepatis in patients with AIDS




      • Cebebral taxoplasmosis




      • Uncomplicated skin infection




      • Others






    • Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Dermatology clinics




      • Pharmaceutical companies




      • Others






    • China Outlook (USD Billion, 2018-2032)




    • Macrolide Antibiotics by Drugs




      • Azithromycin




      • Clarithromycin




      • Erythromycin




      • Fidaxomicin




      • Telithromycin






    • Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)




      • Oral




      • Parenteral






    • Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)




      • Infection due to mycoplasma pneumonia




      • Legionella sp,or Bordetella pertussis




      • Symptomatic cat-scratch disease




      • Bacillary angiomatosis




      • Peliosis hepatis in patients with AIDS




      • Cebebral taxoplasmosis




      • Uncomplicated skin infection




      • Others






    • Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Dermatology clinics




      • Pharmaceutical companies




      • Others






    • Japan Outlook (USD Billion, 2018-2032)




    • Macrolide Antibiotics by Drugs




      • Azithromycin




      • Clarithromycin




      • Erythromycin




      • Fidaxomicin




      • Telithromycin






    • Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)




      • Oral




      • Parenteral






    • Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)




      • Infection due to mycoplasma pneumonia




      • Legionella sp,or Bordetella pertussis




      • Symptomatic cat-scratch disease




      • Bacillary angiomatosis




      • Peliosis hepatis in patients with AIDS




      • Cebebral taxoplasmosis




      • Uncomplicated skin infection




      • Others






    • Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Dermatology clinics




      • Pharmaceutical companies




      • Others






    • India Outlook (USD Billion, 2018-2032)




    • Macrolide Antibiotics by Drugs




      • Azithromycin




      • Clarithromycin




      • Erythromycin




      • Fidaxomicin




      • Telithromycin






    • Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)




      • Oral




      • Parenteral






    • Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)




      • Infection due to mycoplasma pneumonia




      • Legionella sp,or Bordetella pertussis




      • Symptomatic cat-scratch disease




      • Bacillary angiomatosis




      • Peliosis hepatis in patients with AIDS




      • Cebebral taxoplasmosis




      • Uncomplicated skin infection




      • Others






    • Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Dermatology clinics




      • Pharmaceutical companies




      • Others






    • Australia Outlook (USD Billion, 2018-2032)




    • Macrolide Antibiotics by Drugs




      • Azithromycin




      • Clarithromycin




      • Erythromycin




      • Fidaxomicin




      • Telithromycin






    • Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)




      • Oral




      • Parenteral






    • Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)




      • Infection due to mycoplasma pneumonia




      • Legionella sp,or Bordetella pertussis




      • Symptomatic cat-scratch disease




      • Bacillary angiomatosis




      • Peliosis hepatis in patients with AIDS




      • Cebebral taxoplasmosis




      • Uncomplicated skin infection




      • Others






    • Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Dermatology clinics




      • Pharmaceutical companies




      • Others






    • Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)




    • Macrolide Antibiotics by Drugs




      • Azithromycin




      • Clarithromycin




      • Erythromycin




      • Fidaxomicin




      • Telithromycin






    • Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)




      • Oral




      • Parenteral






    • Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)




      • Infection due to mycoplasma pneumonia




      • Legionella sp,or Bordetella pertussis




      • Symptomatic cat-scratch disease




      • Bacillary angiomatosis




      • Peliosis hepatis in patients with AIDS




      • Cebebral taxoplasmosis




      • Uncomplicated skin infection




      • Others






    • Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Dermatology clinics




      • Pharmaceutical companies




      • Others








  • Rest of the World Outlook (USD Billion, 2018-2032)




    • Macrolide Antibiotics by Drugs




      • Azithromycin




      • Clarithromycin




      • Erythromycin




      • Fidaxomicin




      • Telithromycin






    • Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)




      • Oral




      • Parenteral






    • Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)




      • Infection due to mycoplasma pneumonia




      • Legionella sp,or Bordetella pertussis




      • Symptomatic cat-scratch disease




      • Bacillary angiomatosis




      • Peliosis hepatis in patients with AIDS




      • Cebebral taxoplasmosis




      • Uncomplicated skin infection




      • Others






    • Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Dermatology clinics




      • Pharmaceutical companies




      • Others






    • Middle East Outlook (USD Billion, 2018-2032)




    • Macrolide Antibiotics by Drugs




      • Azithromycin




      • Clarithromycin




      • Erythromycin




      • Fidaxomicin




      • Telithromycin






    • Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)




      • Oral




      • Parenteral






    • Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)




      • Infection due to mycoplasma pneumonia




      • Legionella sp,or Bordetella pertussis




      • Symptomatic cat-scratch disease




      • Bacillary angiomatosis




      • Peliosis hepatis in patients with AIDS




      • Cebebral taxoplasmosis




      • Uncomplicated skin infection




      • Others






    • Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Dermatology clinics




      • Pharmaceutical companies




      • Others






    • Africa Outlook (USD Billion, 2018-2032)




    • Macrolide Antibiotics by Drugs




      • Azithromycin




      • Clarithromycin




      • Erythromycin




      • Fidaxomicin




      • Telithromycin






    • Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)




      • Oral




      • Parenteral






    • Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)




      • Infection due to mycoplasma pneumonia




      • Legionella sp,or Bordetella pertussis




      • Symptomatic cat-scratch disease




      • Bacillary angiomatosis




      • Peliosis hepatis in patients with AIDS




      • Cebebral taxoplasmosis




      • Uncomplicated skin infection




      • Others






    • Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Dermatology clinics




      • Pharmaceutical companies




      • Others






    • Latin America Outlook (USD Billion, 2018-2032)




    • Macrolide Antibiotics by Drugs




      • Azithromycin




      • Clarithromycin




      • Erythromycin




      • Fidaxomicin




      • Telithromycin






    • Macrolide Antibiotics Route of administration Outlook (USD Billion, 2018-2032)




      • Oral




      • Parenteral






    • Macrolide Antibiotics Indication Outlook (USD Billion, 2018-2032)




      • Infection due to mycoplasma pneumonia




      • Legionella sp,or Bordetella pertussis




      • Symptomatic cat-scratch disease




      • Bacillary angiomatosis




      • Peliosis hepatis in patients with AIDS




      • Cebebral taxoplasmosis




      • Uncomplicated skin infection




      • Others






    • Macrolide Antibiotics End-user Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Dermatology clinics




      • Pharmaceutical companies




      • Others










Leading companies partner with us for data-driven Insights.
Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid